Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May;32(5):492-500.
doi: 10.1016/j.jdiacomp.2017.12.008. Epub 2017 Dec 27.

The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression

Shan Xing  1 , Gregory S Calip  1 , Alex D Leow  2 , Shiyun Kim  3 , Glen T Schumock  1 , Daniel R Touchette  1 , Todd A Lee  4
Affiliations

The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression

Shan Xing et al. J Diabetes Complications. 2018 May.

Abstract

Aims: To compare adherence and persistence to oral antidiabetic drugs (OAD) between patients who are new users of second generation antipsychotics (SGA) versus new users of other depression therapies in adults with type 2 diabetes mellitus (T2DM) and major depressive disorder (MDD).

Methods: Adults 18-64 years with previously-treated T2DM and MDD (past OAD and SSRI/SNRI use) who are new users of SGA or non-SGA therapies (bupropion, lithium, mirtazapine, thyroid hormone, tricyclic antidepressant) were identified in the 2009-2015 MarketScan® Commercial Claims and Encounters database. Multivariate regression models were used to determine the odds of a ≥10% decline in OAD adherence over 180- and 365-days, and time to OAD discontinuation, adjusting for differences between groups.

Results: A total of 8664 (21.5% SGA), 8311 (22.1% SGA), and 17,524 (21.3% SGA) patients met inclusion criteria for the 180-day adherence, 365-day adherence, and persistence cohorts, respectively. Over 180-days, 16.6% of SGA and 13.3% of non-SGA initiators had a ≥10% decline in OAD adherence (adjusted odds ratio [OR] = 1.41, 95% CI 1.21-1.63). Over 365-days, 22.3% of SGA and 18.9% of non-SGA initiators had a ≥ 10% decline (OR = 1.34, 95% CI 1.17-1.53). Time to OAD discontinuation was similar between groups (adjusted hazard ratio = 1.03, 95% CI 0.94-1.12).

Conclusion: Use of SGA was associated with a 1.3-1.4 times higher odds of a ≥10% decline in OAD adherence. Adherence to OAD is critical for optimal diabetes control and reductions in this magnitude may impact A1C. Close monitoring of OAD adherence after SGA initiation is warranted.

Keywords: Antidepressants; Antipsychotics; Depression; Healthcare administration claims; Medication adherence; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

Duality of Interest

The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1. Non-adherence to oral antidiabetic drug (OAD) therapy comparing second generation antipsychotic (SGA) initiators versus non-SGA initiators in primary and sensitivity analyses
The adjusted odds ratios (OR) and 95% confidence intervals (CI) are graphed for the primary analysis (i.e. ≥10% decline in adherence to OAD comparing the 180 days post-index versus the 180 days pre-index, where adherence was estimated using the average proportion of days covered (PDC) for patients using multiple diabetes drug classes) and the sensitivity analyses where adherence was measured: 1) over 365 days compared to 180 days in the main analysis; 2) using a 80% PDC cut-off where non-adherence was defined as PDC<0.8 calculated over the 180 and 365 days post-index compared to a 10% decline in the main analysis; 3) using the “Diabetes All Class Rate” instead of the average PDC for patients using multiple diabetes drug classes in the main analysis; 4) measuring a ≥20% decline over the 180 and 365 days post versus pre-index compared to 10% decline in the main analysis; and 5) excluding patients with any inpatient admission.
See this image and copyright information in PMC

References

    1. Al-Ruthia YS, Hong SH, Solomon D. Do depressed patients on adjunctive atypical antipsychotics demonstrate a better quality of life compared to those on antidepressants only? A comparative cross-sectional study of a nationally representative sample of the US population. Research in Social & Administrative Pharmacy: RSAP. 11(2):228–40. (n.d.) https://doi.org/10.1016/j.sapharm.2014.06.001. - DOI - PubMed
    1. Pharmacy Quality Alliance. Technical Specifications for PQA Approved Measures. 2014 Retrieved February 28, 2017 from http://www.nbch.org/nbch/files/ccLibraryFiles/Filename/000000003537/1_Ju....
    1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Society of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity. J Clin Psychiatry. 2004;65(2):267–272. https://doi.org/10.2337/diacare.27.2.596. - DOI - PubMed
    1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14747245. - PubMed
    1. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of Medication Adherence and Associated Health Care Costs in an Older Population with Type 2 Diabetes Mellitus: A Longitudinal Cohort Study. Clinical Therapeutics. 2003;25(11):2958–2971. https://doi.Org/10.1016/S0149-2918(03)80347-8. - DOI - PubMed

Publication types

MeSH terms